ENOB Enochian Biosciences

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’s Special Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.

All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.

For complete results on all matters voted on at the meeting, please consult the Company's Form 8-K which will be filed on EDGAR at .

ABOUT THE COMPANY

Renovaro has developed advanced cell, gene, and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, go to their website at

Contact:

Source: Renovaro Bioscience Inc.



EN
25/01/2024

Underlying

ENOBEnochian Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Enochian Biosciences

 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discover...

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Pre...

June 3, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to E...

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. ...

May 22, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Bi...

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According...

May 22, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and valid...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro and Amsterdam University Medical Center Announce Exclusive Co...

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement o...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch